Orthofix CFO sells 4,873 shares for tax withholding

Orthofix Medical Inc.'s CFO Julie Andrews reported a sale of 4,873 shares of common stock on January 16, 2026 at a price of $14.38 per share.

Rhea-AI Filing Summary

Orthofix Medical Inc.'s CFO Julie Andrews reported a sale of 4,873 shares of common stock on January 16, 2026 at a price of $14.38 per share. This was a Form 4 insider transaction.

According to the footnotes, the shares were sold solely to cover tax withholding obligations tied to the settlement of restricted stock units under a pre-existing, mandatory sell-to-cover arrangement approved by the board’s Compensation and Talent Development Committee. The sale was made without any exercise of discretion by the reporting person.

After this transaction, Andrews beneficially owned 58,039 shares of Orthofix common stock, which includes 45,590 previously reported restricted stock units.

Insider Trade Summary

Net Seller: 4,873 shares

Net Sell 1 txn

Insider Andrews Julie

Role CFO

Sold 4,873 shs ($70K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,873	$14.38	$70K

Holdings After Transaction: Common Stock — 58,039 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.
2. F2. Includes 45,590 previously reported restricted stock units.

FAQ

What insider transaction did Orthofix Medical (OFIX) report for its CFO?

The CFO, Julie Andrews, reported selling 4,873 shares of Orthofix Medical common stock on January 16, 2026 at $14.38 per share.

Why did the Orthofix (OFIX) CFO sell 4,873 shares?

The footnotes state the 4,873 shares were sold to satisfy tax withholding obligations related to the settlement of restricted stock units, under a pre-existing mandatory sell-to-cover requirement approved by the board committee, with no discretion exercised by the CFO.

How many Orthofix (OFIX) shares does the CFO own after this Form 4 transaction?

Following the sale, the CFO beneficially owned 58,039 shares of Orthofix common stock, which includes 45,590 previously reported restricted stock units.

What type of security was involved in the Orthofix CFO’s Form 4 filing?

The transaction involved Orthofix Medical Inc. common stock, reported in Table I for non-derivative securities.

Was the Orthofix (OFIX) CFO’s stock sale discretionary?

No. The footnote explains the sale was made under a pre-existing, mandated sell-to-cover requirement to pay taxes and was completed without any exercise of discretion by the reporting person.

What role does Julie Andrews hold at Orthofix Medical (OFIX)?

Julie Andrews is reported as an officer of Orthofix Medical Inc., serving in the role of CFO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrews Julie

(Last) (First) (Middle)

3451 PLANO PARKWAY

(Street)

LEWISVILLE TX 75056

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/16/2026		S(1)		4,873	D	$14.38	58,039(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.

2. Includes 45,590 previously reported restricted stock units.

	/s/ J. Andres Cedron, attorney-in-fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.